IL15 and amyotrophic lateral sclerosis: Another group of markers, embracing the neuropentraxin family members NPTX1, NPTX2, and NPTXR, as well as CRH and IL‐15, did not discriminate SOD1‐ALS from the matched control group, but showed a reduction at both 3 and 12 months of therapy with tofersen, suggesting them as long‐term response markers.